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Type I cGMP-dependent protein kinase (PKG I) plays a
major role in vascular homeostasis mediating smooth
muscle relaxation in response to nitric oxide, but rela-
tively little is known about the regulation of PKG I expres-
sion. Rho family GTPases (including RhoA and Rac1) are
regulated by growth factors and cell adhesion molecules
and modulate cell proliferation and motility as well as
gene expression. We found opposing effects of RhoA and
Rac1 on PKG I expression: (i) cell density-induced
increases in PKG I expression occurred under conditions
of high Rac1 activity and low RhoA activity in post-conflu-
ent cells; (ii) activation of RhoA by calpeptin suppressed
PKG I, whereas down-regulation of RhoA by siRNA
increased PKG I expression; and (iii) PKG I promoter
activity was suppressed in cells expressing active RhoA or
Rho-kinase, but was enhanced in cells expressing active
Rac1, a dominant negative RhoA, or p120 catenin. Sp1
consensus sequences in the PKG I promoter were required
for Rho regulation and bound nuclear proteins in a cell
density-dependent manner, including the Krüppel-like
factor 4 (KLF4). KLF4 was identified as the major trans-
acting factor at two proximal SP1 sites; active RhoA sup-
pressed KLF4 DNA binding and transactivation potential
on the PKG I promoter. We propose a novel mechanism
for cell density-dependent regulation of gene expression
involving Rho and Rac; moreover, suppression of PKG I
expression by RhoA may explain the decrease in vascular
smooth muscle cell PKG I levels found in some models of
hypertension and vascular injury.
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